Clinical Trials Logo

Tacrolimus clinical trials

View clinical trials related to Tacrolimus.

Filter by:

NCT ID: NCT06095895 Not yet recruiting - Pharmacokinetics Clinical Trials

Model Informed preciSion doSIng tO iNdividualise and Optimize Pharmacotherapeutic Treatment

MISSION
Start date: November 15, 2023
Phase:
Study type: Observational

This is a prospective observational study of MIPD in clinical practice for paediatric kidney transplant patients using tacrolimus and mycophenolic acid in Radboudumc. Dose individualization in paediatric kidney transplant patients using the InsightRX platform is performed as standard care, meaning that a pharmacokinetic model and drug levels measured at t=0, t=1 and t=2 hours will be used to calculate the exposure. Based on the estimated exposure, the pharmacist gives a dose recommendation to the physician, who can then modify the dosage of mycophenolic acid or tacrolimus. The selected dose and the measured MPA and tacrolimus concentrations will be used to predict the future exposure. A second exposure measurement will be performed to evaluate whether our model is able to predict future exposure.

NCT ID: NCT05797038 Not yet recruiting - Clinical trials for Idiopathic Membranous Nephropathy

Study on the Application of Hyperspectral Imaging Technique in the Treatment of IMN by TAC

Start date: April 25, 2023
Phase:
Study type: Observational

We propose hyperspectral imaging analysis as a method to identify the efficacy of hormone-tacrolimus therapy for PMN, and to classify sensitive and insensitive patients treated with hormone-tacrolimus regimen. A variety of machine learning models were used to prove that hyperspectral imaging technology could assist patients in selecting the optimal treatment plan, and further explore the predictive indicators of PMN treatment effect.

NCT ID: NCT05089604 Recruiting - Clinical trials for Liver Transplantation

Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations

LCP-TAC
Start date: January 9, 2023
Phase: Phase 4
Study type: Interventional

This is a randomized open label study in de novo liver transplant recipients that aims to compare the risk of tacrolimus induced tremors with once daily extended-release formulation, Envarsus, versus the twice daily immediate-release formulation. Both formulations of tacrolimus are currently approved for the prevention of rejection in liver transplant patients.

NCT ID: NCT04045171 Not yet recruiting - Pharmacokinetics Clinical Trials

Population Pharmacokinetics of Tacrolimus in Nephrotic Syndrome

PISTONS
Start date: August 10, 2019
Phase:
Study type: Observational

This study will use a multi-center, prospective design, with a "Real World Study" model, to include 200 patients with nephrotic syndrome. based on the Population Pharmacokinetics (PPK) model, it will study genotype and clinical factors in patients with nephrotic syndrome, to explore the Pharmacokinetics/ Pharmacodynamics (PK/PD) relationship of Tacrolimus in patients with nephrotic syndrome, and develop an optimal medication regimen.

NCT ID: NCT03864250 Recruiting - Clinical Trial Clinical Trials

Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy

Start date: November 26, 2018
Phase: N/A
Study type: Interventional

This random, open, control and multicenter clinical trial mainly aims to assess the urine protein remission rate of tacrolimus (TAC) monotherapy for idiopathic membranous nephropathy (IMN).

NCT ID: NCT03557203 Recruiting - Clinical trials for Vernal Keratoconjunctivitis

Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis

Start date: June 1, 2018
Phase:
Study type: Observational

To evaluate the therapeutic effects of dermatologic tacrolimus ointment on eyelids to treat refractory vernal keratoconjunctivitis and atopic keratoconjunctivitis.

NCT ID: NCT03358082 Recruiting - Vitiligo Clinical Trials

Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo

Start date: October 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study will evaluate the effectiveness of Tacrolimus 0.03% ointment monotherapy in patients with vitiligo. Patients will be treated for 6 months and followed for 3 months after treatment. All types of vitiligo will be included.

NCT ID: NCT01960322 Completed - Tacrolimus Clinical Trials

Improving Medication-taking After Liver Transplant

I-AM
Start date: August 2014
Phase: Phase 1
Study type: Interventional

The specific aim is to pilot-test our developed intervention manual's ability to improve patients' adherence to medications and medical outcomes (rejection rate, liver enzyme levels) in participating centers.

NCT ID: NCT01055964 Completed - Pharmacokinetics Clinical Trials

a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients

Start date: September 2008
Phase: Phase 3
Study type: Interventional

The aim of this study is to identify the pharmacokinetic differences between two oral forms of Tacrolimus and consequent nephrotoxicity.

NCT ID: NCT00615667 Completed - Kidney Diseases Clinical Trials

Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)

Start date: June 2006
Phase: Phase 3
Study type: Interventional

Exploring the efficacy and safety of Tacrolimus on refractory nephrotic syndrome ; Acquiring the experience of Tacrolimus on the treatment of refractory nephrotic syndrome in Chinese patients.